Search details
1.
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
JAMA
; 330(11): 1042-1053, 2023 09 19.
Article
in English
| MEDLINE | ID: mdl-37638695
2.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Cancer Sci
; 112(6): 2381-2392, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33686753
3.
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Drug Metab Dispos
; 48(9): 796-803, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32581049
4.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Invest New Drugs
; 33(1): 148-58, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25260842
5.
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Cancer
; 120(13): 2016-24, 2014 Jul 01.
Article
in English
| MEDLINE | ID: mdl-24676877
6.
Abemaciclib does not increase the corrected QT interval in healthy participants.
Clin Transl Sci
; 16(9): 1617-1627, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37337637
7.
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.
CPT Pharmacometrics Syst Pharmacol
; 9(9): 523-533, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32683787
8.
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
J Clin Pharmacol
; 60(7): 915-930, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32080863
9.
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Clin Pharmacol Ther
; 105(5): 1187-1195, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30449032
10.
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Clin Pharmacokinet
; 57(3): 335-344, 2018 03.
Article
in English
| MEDLINE | ID: mdl-28540640
11.
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.
Clin Cancer Res
; 24(22): 5543-5551, 2018 11 15.
Article
in English
| MEDLINE | ID: mdl-30082474
12.
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Clin Cancer Res
; 23(8): 1910-1919, 2017 04 15.
Article
in English
| MEDLINE | ID: mdl-27803065
13.
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.
Cancer Chemother Pharmacol
; 57(4): 475-82, 2006 Apr.
Article
in English
| MEDLINE | ID: mdl-16047146
14.
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Cancer Chemother Pharmacol
; 78(2): 281-8, 2016 Aug.
Article
in English
| MEDLINE | ID: mdl-27312735
15.
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Clin Cancer Res
; 8(8): 2488-98, 2002 Aug.
Article
in English
| MEDLINE | ID: mdl-12171874
16.
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
Cancer Chemother Pharmacol
; 53(3): 253-60, 2004 Mar.
Article
in English
| MEDLINE | ID: mdl-14648016
17.
Topoisomerase I interactive agents.
Cancer Chemother Biol Response Modif
; 20: 99-123, 2002.
Article
in English
| MEDLINE | ID: mdl-12703202
18.
Topoisomerase I interactive agents.
Cancer Chemother Biol Response Modif
; 21: 69-101, 2003.
Article
in English
| MEDLINE | ID: mdl-15338741
Results
1 -
18
de 18
1
Next >
>>